What are the fundraising trends in the mental health market?
In our mental health market deck, you will find everything you need to understand the market
SUMMARY
We analyzed every publicly disclosed equity round raised by pure-play mental health companies between January 2024 and May 2026. We only kept disclosed equity rounds of $300K or more, excluded non-clinical wellness and self-help companies, and treated the resulting sample as a public funding tracker for clinical mental health and substance-use diagnosis, treatment, and management.
The dataset shows a mental health market that is larger in dollars but narrower in capital access. Full-year disclosed funding rose from $831.1M across 26 deals in 2024 to $1.0B across 21 deals in 2025, while year-to-date 2026 already reached $631.8M across 11 deals.
Capital in the mental health market is becoming more concentrated. The top 3 deals captured 39.7% of 2024 capital, 67.8% of 2025 capital, and 69.6% of capital in year-to-date 2026.
The latest year-to-date window is strong but fragile. January through May 2026 produced far more capital than the same period in 2025, but Talkiatry, Grow Therapy, and Salma Health alone explain a large share of the apparent recovery.
Round sizes are being pulled upward by large winners. The 2026 year-to-date average round is $57.4M, while the median is $25.0M, which means the typical deal is meaningfully smaller than the headline average suggests.
Psychiatry Care Platforms lead year-to-date 2026 capital with $230.0M, or 36.4% of dollars, from only 18.2% of deals. That gap shows how strongly investors value psychiatric capacity, medication-management workflows, and reimbursement-linked infrastructure.
Therapy Care Providers have rebounded in 2026 after a weak 2025. The category raised $196.0M through May 2026, driven mainly by Grow Therapy and Tava Health, but the rebound is concentrated in scaled provider infrastructure rather than broad funding for generic therapy startups.
Clinical Mental Health Apps remain active but capital-light. They account for 27.3% of year-to-date 2026 deals but only 6.5% of capital, which suggests investors are testing AI and workflow software while reserving larger checks for businesses closer to reimbursement and care delivery.
North America still dominates the mental health market. It captured 99.1% of year-to-date 2026 dollars and 90.9% of deals, while Asia-Pacific appeared through one small India-based round and Europe had no qualifying deal in the latest year-to-date sample.
The strongest overall signal is that the mental health market is healthier at the top than in the middle. Large rounds are available for scaled care platforms, psychiatry infrastructure, advanced clinics, and psychiatric therapeutics, but ordinary app, therapy, or niche-provider companies face a more selective funding environment.
This chart, featured in our mental health market deck, shows how market revenue is split across customer segments in the mental health market
Is more or less capital going into the mental health market?
More capital is going into the mental health market, but the increase is not a simple broad-based funding recovery. Full-year disclosed capital rose from $831.1M in 2024 to $1.0B in 2025, even as the number of qualifying deals fell from 26 to 21.
The practical interpretation is that the mental health market attracted more dollars in 2025, but fewer companies captured those dollars. A market with rising capital and falling deal count is not expanding through breadth. It is concentrating capital into fewer perceived winners.
The freshest year-to-date comparison is even more aggressive. From January through May 2026, the mental health market raised $631.8M across 11 deals, compared with $131.15M across 6 deals over the same calendar window in 2025.
That does not mean every mental health company is suddenly finding fundraising easy. Talkiatry’s $210M financing, Grow Therapy’s $150M Series D, Salma Health’s $80M Series A, and Gilgamesh Pharma’s $60M Series A account for much of the 2026 total.
The real signal is selective capital return. The mental health market is rewarding companies that can plausibly own high-value clinical workflows, medication management, payer access, provider capacity, advanced treatment infrastructure, or psychiatric drug-development upside.
Is mental health funding driven by more deals or larger rounds?
Mental health funding is being driven primarily by larger rounds, not simply by more deals. The clean full-year comparison shows capital increasing from $831.1M in 2024 to $1.0B in 2025 while deal count declined from 26 to 21.
Round-size metrics confirm the same pattern. Average round size rose from $32.0M in 2024 to $47.6M in 2025, while the median round fell from $16.0M to $12.5M. That means the average increased because the largest rounds became much larger, not because the typical company raised more.
The 2026 year-to-date window is more encouraging because deal count also rose versus the same period in 2025. The mental health market recorded 11 qualifying deals from January through May 2026 versus 6 over the comparable 2025 period.
Even there, larger rounds are doing most of the work. Capital rose from $131.15M to $631.8M, average round size jumped from $21.86M to $57.4M, and the top 3 deals represented 69.6% of year-to-date 2026 dollars.
The strongest reading is that the mental health market is showing both more activity and larger rounds in 2026, but large rounds remain the main driver. For deeper benchmarks on deal sizes, medians, and concentration, see the mental health market deck.
Is mental health capital moving toward later-stage or earlier-stage companies?
Mental health capital is moving back toward later-stage companies in 2026, even though 2025 temporarily looked more early-stage on paper. The answer depends on whether stage labels are read literally or interpreted through deal size and company type.
In 2024, Seed, Series A, and unknown-stage rounds captured 21.4% of capital, while Series B and later rounds captured 78.6%. In 2025, Seed, Series A, and unknown-stage rounds rose to 56.4% of capital, which looks like a major early-stage shift.
That early-stage conclusion needs a qualifier. Much of the 2025 early-stage capital came from very large psychiatric medication Series A rounds, including Syremis, Draig, and Newleos. A $165M or $140M psychiatric medicine Series A behaves more like an institutional life-sciences platform financing than an ordinary early-stage digital health round.
The fresher 2026 signal points back toward later-stage winners. From January through May 2026, Series B and later rounds captured 63.3% of capital, while Seed and Series A captured 36.7%.
The practical takeaway is that the mental health market is not simply moving earlier or later. It is funding both large new therapeutic and clinic theses and proven scaled care platforms, but the largest 2026 checks are again going to companies with existing scale.
This chart, featured in our mental health market deck, compares the main business model options for tele-mental health platforms
Is the mental health market maturing or still experimental?
The mental health market is maturing at the top, but it still has an experimental long tail. The strongest evidence of maturity is that most capital is going to companies with reimbursement, provider networks, psychiatry, advanced treatment infrastructure, or clinical-stage therapeutics.
The 2025 full-year data shows this clearly. Funding rose to $1.0B, but only 21 deals qualified, and the largest 5 deals captured 82.1% of all capital. That is not a market where capital is spread evenly across every new entrant.
The 2026 stage mix adds another maturity signal. Series D+ rounds accounted for 57.0% of year-to-date capital, led by Talkiatry and Grow Therapy. Investors are writing very large checks when a company has already shown scale, payer access, and operational leverage.
At the same time, the mental health market is not fully mature. Series A is the most common stage in year-to-date 2026, with 54.5% of deals, and Clinical Mental Health Apps remain active even though they receive smaller checks.
The most accurate conclusion is that the mental health market has matured around business-model quality. The question is no longer whether mental health demand exists. The question is which companies can convert demand into reimbursable, scalable, clinically credible care.
Are new startups still entering the mental health market?
Yes, new startups are still entering the mental health market, but new entrants are not where most capital consistently goes. First financings represented 15.4% of deals in 2024, 47.6% in 2025, and 36.4% in year-to-date 2026.
The jump from 2024 to 2025 is meaningful. The mental health market moved from 4 first financings in 2024 to 10 in 2025, even though total deal count fell. That means the market did not shut the door on formation.
But the composition of those first financings matters. In 2025, a large share of first-financing capital came from psychiatric medication companies such as Newleos and Syremis, not from small consumer-facing therapy apps.
So far in 2026, first financings include Oasys, Salma Health, Amani Therapeutics, and Gilgamesh Pharma. These companies sit in AI clinical infrastructure, integrated brain-health clinics, and psychiatric medication services.
The direct answer is that new startups are still entering the mental health market, but the bar is high. For a broader view of startup formation, first financings, and category entry, see the full mental health market report.
Are more investors entering the mental health market?
More investors appear to be entering or re-entering the mental health market, but the signal is better read as broader syndicate diversity than as a rush of repeat specialist investors. The dataset identifies about 77 unique disclosed investors in 2024, about 80 in 2025, and 44 so far in 2026.
Because 2026 covers only January through May, 44 disclosed investors across 11 deals is a meaningful level of breadth. The investor base has not disappeared, even though funding is concentrating into fewer larger rounds.
The type of investor has changed over time. In 2024, major generalist and growth investors backed care-delivery platforms such as Talkiatry, Headway, Grow Therapy, InStride, Pelago, and Spring Health. In 2025, the repeat investor signal was strongest in psychiatric medication services, where Goldman Sachs Alternatives, Novo Holdings, and Sanofi or Sanofi Ventures appeared more than once.
So far in 2026, the mental health market has attracted a high-quality but fragmented investor base. Tier-1 names include General Catalyst, Andreessen Horowitz, Perceptive Advisors, ARCH Venture Partners, Mubadala Capital, TCV, Goldman Sachs Alternatives, Menlo Ventures, Sequoia Capital, RTW Investments, Headline, M13, Zetta Venture Partners, Centana Growth Partners, and Catalyst Investors.
The strongest conclusion is that investor participation remains healthy, but conviction is thesis-specific. Growth investors like scaled provider platforms, life-sciences investors like psychiatric medication assets, infrastructure investors like AI clinical workflow, and healthcare specialists like reimbursement-linked care models.
This chart, featured in our mental health market deck, illustrates yearly funding for mental health startups
Are top investors getting more or less active in mental health?
Top investors are getting more selective rather than uniformly more active in the mental health market. The evidence does not show a growing group of elite investors repeatedly backing many mental health deals in the same year.
In 2024, only GreyMatter Capital and Hopelab appeared in more than one disclosed deal among named investors. That is a low repeat-investor count for a market with 26 qualifying deals and $831.1M of disclosed capital.
In 2025, repeat activity became slightly more concentrated, but mainly in psychiatric medication services. Goldman Sachs Alternatives, Novo Holdings, and Sanofi or Sanofi Ventures each appeared in more than one deal, which points to repeat conviction in neuropsychiatric therapeutics rather than in generic care delivery.
So far in 2026, no disclosed institutional investor appears in more than one included deal. That may partly reflect the limited year-to-date sample, but it also shows that current activity is not being led by one dominant repeat investor group.
The direct answer is that top investors are not getting more active in the sense of doing many more deals. They are writing large checks into specific companies that match their thesis: scaled care platforms, psychiatry infrastructure, advanced clinic networks, or psychiatric medication platforms.
Which mental health subcategories are gaining momentum?
The subcategories gaining momentum in the mental health market are Psychiatry Care Platforms, Mental Health Clinics, parts of Psychiatric Medication Services, and scaled Therapy Care Providers. Clinical Mental Health Apps are gaining deal-count momentum, but not capital momentum.
The biggest full-year shift from 2024 to 2025 was Psychiatric Medication Services. The category had no qualifying capital in 2024, then captured $771.0M in 2025, or 77.1% of total mental health funding, across only 4 deals.
Mental Health Clinics also gained momentum. The category rose from $45.0M across 2 deals in 2024 to $90.0M across 4 deals in 2025, then continued into 2026 with Salma Health’s $80M Series A.
Psychiatry Care Platforms are gaining strong current-year momentum. The category fell from $204.0M in 2024 to $29.25M in 2025, but rebounded to $230.0M through May 2026, mainly because of Talkiatry and Blossom Health.
Therapy Care Providers show a more nuanced rebound. The category dominated 2024 with $450.0M, collapsed to $40.5M in 2025, then rebounded to $196.0M through May 2026. We cover this category shift in more detail in the market report covering mental health subcategories.
Which mental health subcategories are losing momentum?
The subcategories losing momentum in the mental health market are Addiction Treatment Services and, on a full-year basis, general Therapy Care Providers and Psychiatry Care Platforms, though the last two show signs of recovering in 2026. Clinical Mental Health Apps are also weak on capital intensity despite healthy deal activity.
Addiction Treatment Services show the clearest current weakness. In 2024, addiction treatment companies raised $104.0M across 3 deals. In 2025, the category fell to $47.5M across 3 deals. Through May 2026, there are no qualifying Addiction Treatment Services deals in the included dataset.
The absence of addiction rounds is notable because the clinical and social need is large. The likely issue is not demand; it is the difficulty of producing repeatable, venture-scale, publicly disclosed financing events in a category with complex reimbursement, regulation, and outcomes measurement.
Therapy Care Providers lost major momentum from 2024 to 2025, falling from $450.0M across 13 deals to $40.5M across 4 deals. The 2026 rebound suggests therapy care is not abandoned, but investors are repricing it around scaled, reimbursed, provider-enabling platforms.
Clinical Mental Health Apps face a different weakness. They are fundable, but capital-light. In year-to-date 2026, they represent 27.3% of deals and only 6.5% of capital, which means investors are testing the app and AI layer without yet underwriting it like a category winner.
This chart, featured in our mental health market deck, shows why Talkspace is winning in mental health
Which regions are gaining momentum in mental health funding?
North America is still the dominant region in mental health funding, but Europe gained episodic capital momentum in 2025 and Asia-Pacific has a small current-year entry in 2026. The answer depends on whether momentum is measured by capital, deal count, or freshness.
The full-year comparison from 2024 to 2025 shows Europe gaining capital share. Europe rose from $16.8M in 2024 to $141.35M in 2025, increasing from 2.0% to 14.1% of disclosed capital.
That European signal was meaningful but concentrated. Draig Therapeutics’ $140M financing explains almost the entire regional increase, so Europe did not suddenly become broad-based across mental health care delivery, clinics, apps, addiction, and psychiatry platforms.
The freshest 2026 comparison shows Asia-Pacific appearing through Amaha’s roughly $6M financing in India. Asia-Pacific had no qualifying deals in 2024 or 2025, then accounted for 1 of 11 year-to-date 2026 deals.
The best conclusion is that Europe gained episodic 2025 momentum through psychiatric therapeutics, Asia-Pacific is showing a small early 2026 signal, and North America remains the only consistent, broad, venture-scale mental health funding base.
Which regions are losing momentum in mental health funding?
Europe is losing momentum in the freshest mental health funding comparison after a strong but concentrated 2025. North America is not losing momentum in any meaningful capital sense.
The full-year 2025 comparison made Europe look stronger because it rose to $141.35M of disclosed funding. But that gain was fragile because it depended heavily on Draig Therapeutics. When one round explains nearly the entire regional increase, the signal is not broad regional deepening.
So far in 2026, Europe has no qualifying deals through May, while North America has 10 deals and Asia-Pacific has 1. Because 2026 is incomplete, the absence of European deals should not be overinterpreted, but the current evidence is clearly weaker.
The Middle East also does not show sustained momentum. It appeared in 2025 through Mentaily’s $3M clinical mental health app round, but there is no qualifying Middle East deal in the year-to-date 2026 sample.
Latin America and Africa have no qualifying deals in 2024, 2025, or year-to-date 2026. That absence suggests that venture-scale, publicly disclosed clinical mental health financing remains highly uneven across global regions.
Is mental health becoming more global or regionally concentrated?
The mental health market is still regionally concentrated, not meaningfully global. North America captured 98.0% of capital in 2024, 85.6% in 2025, and 99.1% through May 2026.
By deal count, North America represented 92.3% in 2024, 85.7% in 2025, and 90.9% so far in 2026. Those shares leave little room for a truly global funding market.
The strongest argument for globalization came in 2025, when Europe captured 14.1% of capital and the Middle East appeared with one deal. But the European capital share came mostly from one psychiatric medication round, while the Middle East contribution was only $3M.
The 2026 year-to-date comparison pulls the market back toward regional concentration. North America has almost all capital, Asia-Pacific has one small deal, and Europe and the Middle East have no qualifying deals through May.
The better interpretation is that the mental health market is globally searchable but not globally scaled. For a fuller regional breakdown, see the full market view on mental health geography.
This chart, featured in our mental health market deck, shows how teletherapy adoption has driven growth in the mental health market over time
Is mental health capital moving toward proven winners or new opportunities?
Mental health capital is moving toward both proven winners and new opportunities, but the largest checks are increasingly going to proven winners or highly credentialed new platforms. The mental health market is best understood as a barbell market.
The proven-winner side is obvious in 2024 and 2026. In 2024, large follow-on rounds went to Talkiatry, Headway, Spring Health, Grow Therapy, Two Chairs, Pelago, Boulder Care, Brightside, and others. In 2026, the biggest checks so far include Talkiatry’s $210M Series D+ and Grow Therapy’s $150M Series D+.
The new-opportunity side was especially strong in 2025. First financings represented 47.6% of deals and 33.9% of capital, up sharply from 15.4% of deals and 2.7% of capital in 2024.
But the new opportunities that received large checks were not ordinary seed-stage app companies. They were psychiatric medication platforms, advanced treatment models, and clinic-linked businesses with institutional credibility.
The strongest conclusion is that the mental health market is not funding novelty for its own sake. It is funding either proof or unusually credible potential, especially when a company can connect clinical specificity to reimbursement, infrastructure, medication, or outcomes.
Is the mental health market becoming winner-takes-most?
The mental health market is becoming more winner-takes-most in capital allocation, even if the underlying care market remains fragmented. The clearest indicator is capital concentration.
In 2024, the top 3 deals captured 39.7% of total disclosed capital. In 2025, the top 3 captured 67.8%. So far in 2026, the top 3 captured 69.6%. That is a major increase in concentration.
The bottom-half share reinforces the same point. In 2024, the bottom 50% of deals captured 14.5% of capital. In 2025, the bottom half captured only 6.0%. So far in 2026, the bottom half captured 10.6%.
The winner-takes-most pattern is not identical across categories. In 2025, concentration came mainly from psychiatric medication services. In 2026, it is driven by Talkiatry, Grow Therapy, Salma Health, and Gilgamesh Pharma.
The operating market may remain fragmented because youth therapy, psychiatric medication, severe mental illness clinics, addiction treatment, AI workflow software, and interventional psychiatry are different businesses. But within each fundable category, investors increasingly prefer a small number of companies that can plausibly own distribution, clinical credibility, payer access, or scientific upside.
Is the next wave of mental health winners becoming visible?
Yes, the next wave of mental health winners is becoming visible, but the winners are not necessarily consumer-facing therapy brands. The emerging winners are companies that control reimbursed access, psychiatric capacity, clinical infrastructure, advanced treatment pathways, or psychiatric therapeutics.
The clearest visible winners on the care-delivery side are Grow Therapy, Talkiatry, Tava Health, and possibly Salma Health. Grow Therapy raised $75M in 2024 and $150M in 2026. Talkiatry raised $130M in 2024 and $210M in 2026. Tava raised $20M in 2024 and $40M in 2026.
These repeat financings matter because they show companies graduating across cycles. Repeated access to capital is a stronger winner signal than a single headline financing.
On the psychiatric medication side, MapLight, Syremis, Draig, Newleos, Gilgamesh, and Amani define the new high-capital therapeutics wave. The evidence is especially strong for the category because Psychiatric Medication Services went from no qualifying capital in 2024 to $771.0M in 2025 and $85.0M through May 2026.
The likely winners are reimbursement-native, clinically specific, infrastructure-heavy, or scientifically differentiated companies. For more context on the companies and signals that separate durable winners from one-off experiments, see the deeper analysis of the mental health market.
As this chart shows, and as featured in our mental health market deck, search interest in men’s mental health has been rising steadily
Is the mental health funding landscape fragmenting or consolidating?
The mental health funding landscape is consolidating in dollars but fragmenting in themes. This is one of the most important patterns in the mental health market.
The consolidation signal is clear. The top 3 deals captured 39.7% of capital in 2024, 67.8% in 2025, and 69.6% so far in 2026. The top 10 deals captured 78.9% of capital in 2024, 92.8% in 2025, and 99.3% so far in 2026.
But the thematic fragmentation signal is also real. In 2025, Psychiatric Medication Services, Mental Health Clinics, Therapy Care Providers, and Clinical Mental Health Apps each produced 4 deals, while Addiction Treatment Services had 3 and Psychiatry Care Platforms had 2.
That means investors are not converging on one narrow definition of the mental health market. They are converging on a few rules: reimbursement matters, clinical specificity matters, scale matters, and provider capacity matters.
The strongest answer is that the funding landscape is consolidating financially and fragmenting strategically. More dollars are going to fewer companies, but those companies are spread across several theses rather than one single category.
Where is investor attention shifting in mental health?
Investor attention in the mental health market is shifting toward reimbursement-native care delivery, psychiatry infrastructure, advanced clinics, psychiatric medication services, and clinically embedded AI. It is shifting away from generic mental health apps, wellness-adjacent products, and broad therapy access models without payer integration or clinical differentiation.
The full-year 2024 market was dominated by Therapy Care Providers, which captured $450.0M and 13 deals. That was the year of scaled therapy access, provider networks, payer integration, and employer or health-plan distribution.
In 2025, attention shifted dramatically toward Psychiatric Medication Services. The category captured $771.0M, or 77.1% of total capital, across only 4 deals. That moved the market narrative from “how do we deliver therapy and psychiatry at scale?” to “can neuropsychiatric therapeutics produce venture-scale outcomes again?”
So far in 2026, attention has shifted again toward a hybrid of scaled care platforms and psychiatry infrastructure. Talkiatry, Grow Therapy, Salma, Blossom, Tava, Somethings, Jimini, Oasys, Amani, and Gilgamesh show where investor interest sits: provider capacity, psychiatry workflows, payer coverage, AI clinical infrastructure, interventional brain-health care, and serious psychiatric therapeutics.
The clearest attention shift is away from consumer demand and toward system bottlenecks. Investors already believe mental health demand exists; the investable question is who can expand capacity, manage reimbursement, improve clinical workflows, prove outcomes, or develop differentiated treatments. For ongoing tracking of these shifts, see the mental health market report.
All the funding deals in the mental health market from 2024 to Apr 2026
The table below lists every disclosed funding round in the supplied mental health dataset from January 2024 through April 2026, covering therapy providers, psychiatry platforms, clinical mental-health apps, addiction treatment services, mental-health clinics, and psychiatric medication services.
Each row shows the company, the fundraising date, what the company does, its category, the funding stage, the round size, the region, whether it was a first financing or a follow-on, the tier-1 investor if any, and the announcement source. For the broader investability view, see our market deck.
| Company | Date | What they do | Category | Stage | Deal size | Region | First/Follow-on | Tier 1 investor(s) | Source |
|---|---|---|---|---|---|---|---|---|---|
| Tava Health | Apr 2026 | Technology-driven mental health services platform serving providers, employers, and health plans with virtual and in-person therapy access, practice infrastructure, and care navigation. | Therapy Care Providers | Series C | $40M | North America | Follow-on | Centana Growth Partners, Catalyst Investors | Tava Health |
| Jimini Health | Mar 2026 | Clinician-supervised, patient-facing AI infrastructure for behavioral health providers, with a Sage assistant supporting patients between sessions. | Clinical Mental Health Apps | Seed | $17M | North America | Follow-on | M13, Zetta Venture Partners | Jimini Health |
| Amaha | Mar 2026 | India-based mental health platform providing treatment for anxiety, depression, ADHD, and OCD through clinical expertise and technology-led tools. | Therapy Care Providers | Series A | $6M | Asia-Pacific | Follow-on | None clearly tier-1 globally; Fireside is a recognized India-focused VC | Entrackr |
| Blossom Health | Mar 2026 | AI operating system for psychiatry, pairing psychiatrists and psychiatric nurse practitioners with clinical copilots, administrative agents, workflows, and medication-decision support. | Psychiatry Care Platforms | Series A | $20M | North America | Follow-on | Headline; Village Global is notable | PR Newswire |
| Gilgamesh Pharma | Mar 2026 | Clinical-stage neuroscience company developing novel psychiatric medicines, including blixeprodil for major depressive disorder and a broader neuropsychiatric therapeutics pipeline. | Psychiatric Medication Services | Series A | $60M | North America | First financing | None clearly tier-1 by general VC convention; Satori Neuro is specialist lead | PR Newswire |
| Amani Therapeutics | Mar 2026 | Newly formed biotech developing AM-01, a fixed-dose clozapine-based product intended to improve treatment for serious neuropsychiatric disorders, especially schizophrenia. | Psychiatric Medication Services | Series A | $25M | North America | First financing | RTW Investments | Business Wire |
| Grow Therapy | Mar 2026 | Mental health platform enabling licensed providers to deliver in-person and online therapy and psychiatric care, with payer, employer, and health-system integrations. | Therapy Care Providers | Series D+ | $150M | North America | Follow-on | TCV, Goldman Sachs Alternatives, Menlo Ventures, Sequoia Capital | PR Newswire |
| Salma Health | Feb 2026 | Integrated brain and mental health clinic platform combining interventional psychiatry, diagnostics, rapid-acting treatments, intensive care programs, telehealth, research, and AI-enabled coordination. | Mental Health Clinics | Series A | $80M | North America | First financing | ARCH Venture Partners, Mubadala Capital | Business Wire |
| Talkiatry | Feb 2026 | Full-stack virtual psychiatry provider group employing psychiatrists and therapists, delivering in-network psychiatric and therapy care across the U.S. | Psychiatry Care Platforms | Series D+ | $210M | North America | Follow-on | Andreessen Horowitz, Perceptive Advisors | PR Newswire |
| Somethings | Feb 2026 | Digital mental health platform for teens and young adults, connecting users aged 13–26 with Certified Peer Specialist mentors for early support. | Clinical Mental Health Apps | Series A | $19.2M | North America | Follow-on | General Catalyst | PR Newswire |
| Oasys Health | Jan 2026 | AI-native operating system for behavioral health unifying practice management, clinical decision support, documentation, billing, scheduling, insurance workflows, and physiological-data integration. | Clinical Mental Health Apps | Seed | $4.6M | North America | First financing | None clearly tier-1 | PR Newswire |
| Syremis Therapeutics | Dec 2025 | Clinical-stage psychiatric-medicine developer for schizophrenia, other psychiatric conditions, major depressive disorder, and bipolar depression. | Psychiatric Medication Services | Series A | $165M | North America | First financing | Third Rock Ventures, Bain Capital Life Sciences, GV | Syremis |
| Radial | Dec 2025 | Interventional psychiatry clinic network for advanced brain-medicine treatments such as TMS and Spravato. | Mental Health Clinics | Series A | $50M | North America | First financing | General Catalyst, Founder Collective, BoxGroup | Radial |
| Circular Genomics | Dec 2025 | Circular-RNA precision medicine tools and diagnostics for neurology and psychiatry. | Clinical Mental Health Apps | Series A | $15M | North America | Follow-on | Alzheimer’s Drug Discovery Foundation | Circular Genomics |
| FamilyWell Health | Nov 2025 | Women’s mental health care embedded into women’s health practices, including coaching, therapy, and psychiatry. | Mental Health Clinics | Series A | $8M | North America | Follow-on | .406 Ventures | Yahoo Finance |
| Amae Health | Nov 2025 | Outpatient care model for severe mental illness, combining clinic operations, psychiatry, therapy, and precision-care tools. | Mental Health Clinics | Series B | $25M | North America | Follow-on | Altos Ventures, 8VC, Cedars-Sinai Ventures | Business Wire |
| Triplemoon | Oct 2025 | Virtual pediatric mental health platform integrated with primary care clinics. | Therapy Care Providers | Seed | $3.5M | North America | First financing | None disclosed | Business Wire |
| Everbright Health | Oct 2025 | Tech-enabled services platform helping mental health providers deliver TMS, Spravato, and other advanced interventions. | Mental Health Clinics | Seed | $7M | North America | First financing | None disclosed | PR Newswire |
| Marble Health | Oct 2025 | School-linked youth mental health provider connecting students with licensed therapists. | Therapy Care Providers | Series A | $15.5M | North America | Follow-on | Khosla Ventures, Town Hall Ventures | PR Newswire |
| Affect Therapeutics | Sep 2025 | Virtual clinic for substance use and co-occurring mental health disorders using therapy, medications, contingency management, and behavioral science. | Addiction Treatment Services | Series B | $26M | North America | Follow-on | Providence Ventures | Affect Therapeutics |
| Cerebral | Sep 2025 | Virtual behavioral-health provider offering therapy and medication management. | Psychiatry Care Platforms | Unknown | $25M | North America | Follow-on | None disclosed | Behavioral Health Business |
| MapLight Therapeutics | Jul 2025 | Clinical-stage psychiatric and CNS medicines, including schizophrenia and Alzheimer’s disease psychosis programs. | Psychiatric Medication Services | Series D+ | $372.5M | North America | Follow-on | Forbion, Goldman Sachs Alternatives, Sanofi, T. Rowe Price, Novo Holdings, 5AM Ventures | MapLight Therapeutics |
| Clearly | Jul 2025 | AI-driven mental health care combining licensed therapists, video sessions, and AI companions. | Clinical Mental Health Apps | Seed | $1.35M | Europe | First financing | None disclosed | Vestbee |
| Handspring Health | Jun 2025 | Evidence-based virtual therapy for youth, young adults, and families. | Therapy Care Providers | Series A | $12M | North America | Follow-on | NextView Ventures | Handspring Health |
| Draig Therapeutics | Jun 2025 | Clinical-stage neuropsychiatric drug developer with a lead program for major depressive disorder. | Psychiatric Medication Services | Series A | $140M | Europe | Follow-on | Access Biotechnology, Canaan Partners, SR One, Sanofi Ventures, SV Health Investors | Draig Therapeutics |
| Mentaily | May 2025 | AI-powered mental health assessment, triage, and diagnosis platform. | Clinical Mental Health Apps | Seed | $3M | Middle East | First financing | None disclosed | HIT Consultant |
| Noma Therapy | Apr 2025 | Insurance-covered virtual ketamine-assisted psychotherapy, therapy, and medication management. | Psychiatry Care Platforms | Seed | $4.25M | North America | First financing | None disclosed | PRWeb |
| Jones / HC Jones | Apr 2025 | Nicotine-cessation product and app using nicotine replacement therapy and behavioral support. | Addiction Treatment Services | Unknown | $9M | North America | First financing | None disclosed | Behavioral Health Business |
| Ria Health | Mar 2025 | Telehealth alcohol-use-disorder treatment combining medical science, technology, and clinician support. | Addiction Treatment Services | Series B | $12.5M | North America | Follow-on | SV Health Investors, SOSV | Business Wire |
| Sonar Mental Health | Feb 2025 | AI-powered youth mental health support platform for schools, with human and clinical escalation. | Clinical Mental Health Apps | Seed | $2.4M | North America | First financing | GSR Ventures | PR Newswire |
| Newleos Therapeutics | Feb 2025 | Clinical-stage neuropsychiatric medicines for anxiety, substance use disorders, and related mental-health conditions. | Psychiatric Medication Services | Series A | $93.5M | North America | First financing | Goldman Sachs Alternatives, Novo Holdings, DCVC Bio | Business Wire |
| Little Otter | Feb 2025 | Digital whole-family mental health care for children and families. | Therapy Care Providers | Unknown | $9.5M | North America | Follow-on | CRV, Pivotal Ventures | Business Wire |
| Jimini Health | Nov 2024 | AI-backed therapy platform matching patients with licensed clinicians. | Therapy Care Providers | Seed | $8M | North America | First financing | Unknown | Behavioral Health Business |
| Fort Health | Nov 2024 | Virtual pediatric mental-health care integrated with pediatricians and payers. | Therapy Care Providers | Unknown | $5.5M | North America | Follow-on | Twelve Below | PR Newswire |
| Nema Health | Nov 2024 | Digital trauma and PTSD care platform offering therapy, psychiatric medication management, and peer support. | Psychiatry Care Platforms | Series A | $14M | North America | Follow-on | Unknown | Behavioral Health Business |
| Allswell | Oct 2024 | Virtual therapy provider designed for LGBTQ+ adults. | Therapy Care Providers | Seed | $1.3M | North America | First financing | Techstars | FemTech Insider |
| BeMe Health | Aug 2024 | Digital behavioral-health platform for teen mental health. | Clinical Mental Health Apps | Unknown | $12.5M | North America | Follow-on | Flare Capital, Polaris Partners | Behavioral Health Business |
| Meela | Aug 2024 | Therapist-patient matching platform focused on mental-health care. | Therapy Care Providers | Seed | $2.8M | Europe | First financing | Peak, Calm/Storm Ventures | PVCNR |
| Spring Health | Jul 2024 | Employer and health-plan mental-health solution offering behavioral-care access. | Therapy Care Providers | Series D+ | $100M | North America | Follow-on | Generation Investment Management, Kinnevik, Northzone | Spring Health |
| Headway | Jul 2024 | Platform helping patients find in-network therapists and helping clinicians accept insurance. | Therapy Care Providers | Series D+ | $100M | North America | Follow-on | Spark Capital, Andreessen Horowitz, Thrive Capital, Accel, Forerunner Ventures | PR Newswire |
| Seven Starling | Jul 2024 | Virtual women’s behavioral-health provider, especially maternal and perinatal mental health. | Therapy Care Providers | Series A | $10.9M | North America | Follow-on | Unknown | Rosenman Institute |
| Talkiatry | Jun 2024 | National in-network psychiatry and therapy provider with virtual behavioral-health care. | Psychiatry Care Platforms | Series C | $130M | North America | Follow-on | Andreessen Horowitz, Perceptive Advisors | PR Newswire |
| Marigold Health | Jun 2024 | Technology-enabled peer recovery support for people with substance-use disorder. | Addiction Treatment Services | Series A | $11M | North America | Follow-on | Rock Health, KdT Ventures | Business Wire |
| Grow Therapy | May 2024 | Therapy marketplace and provider enablement platform for insurance-covered mental-health care. | Therapy Care Providers | Series B | $75M | North America | Follow-on | TCV, SignalFire | Grow Therapy |
| TadHealth | May 2024 | School mental-health technology and services platform. | Clinical Mental Health Apps | Seed | $1.6M | North America | Follow-on | None identified | Business Wire |
| Boulder Care | May 2024 | App-based telehealth treatment for opioid and alcohol use disorder. | Addiction Treatment Services | Series C | $35M | North America | Follow-on | Advance Venture Partners, Stripes | GeekWire |
| Backpack Healthcare | May 2024 | Online pediatric mental-health provider offering teletherapy and app-enabled care. | Therapy Care Providers | Series A | $14M | North America | Follow-on | Techstars, Hopelab | PR Newswire |
| Amae Health | Apr 2024 | Value-based, psychiatry-led care model for severe mental illness. | Mental Health Clinics | Series A | $15M | North America | Follow-on | 8VC | PR Newswire |
| Clarity Pediatrics | Apr 2024 | Pediatric chronic-care startup beginning with ADHD diagnosis and therapy. | Psychiatry Care Platforms | Seed | $10M | North America | First financing | Unknown | TechCrunch |
| Two Chairs | Apr 2024 | In-person and virtual therapy provider focused on patient-therapist matching and outcomes. | Therapy Care Providers | Series C | $72M | North America | Follow-on | Amplo | TechCrunch |
| Pelago | Mar 2024 | Digital substance-use management clinic for tobacco, alcohol, and opioid treatment. | Addiction Treatment Services | Series C | $58M | North America | Follow-on | Atomico, Kinnevik, Y Combinator, Eight Roads | Pelago |
| InStride Health | Mar 2024 | Outpatient specialty pediatric anxiety and OCD treatment. | Mental Health Clinics | Series B | $30M | North America | Follow-on | General Catalyst | InStride Health |
| Brightside Health | Mar 2024 | Telemental-health provider for anxiety, depression, mood disorders, and crisis psychiatry. | Psychiatry Care Platforms | Series C | $33M | North America | Follow-on | Unknown | Business Wire |
| Tava Health | Mar 2024 | Digital mental-health platform connecting members with therapists, sold through employers and payers. | Therapy Care Providers | Series B | $20M | North America | Follow-on | Catalyst Investors | PR Newswire |
| Limbic | Mar 2024 | Clinical mental-health AI used by providers and health systems for mental-health assessment and support. | Clinical Mental Health Apps | Series A | $14M | Europe | Follow-on | Khosla Ventures | Business Wire |
| Blackbird Health | Feb 2024 | Integrated, technology-backed pediatric and young-adult mental-health provider. | Psychiatry Care Platforms | Series A | $17M | North America | Follow-on | Define Ventures | PR Newswire |
| Headlight | Feb 2024 | Tech-forward mental-health practice offering virtual and in-person therapy. | Therapy Care Providers | Unknown | $18M | North America | Follow-on | Matrix | PR Newswire |
| Vita Health | Jan 2024 | Telehealth suicide-prevention and behavioral-health care for youth and adults. | Therapy Care Providers | Series A | $22.5M | North America | Follow-on | CVS Health Ventures, Flare Capital Partners | MobiHealthNews |
INSIGHTS
The insights below come from reviewing every disclosed equity round in the mental health market between January 2024 and May 2026, with special attention to the year-to-date 2026 funding signal.
- The year-to-date 2026 funding market is not broad-based; it is top-heavy. The top 3 deals captured 69.6% of all disclosed capital, so the headline recovery can be overstated if the analysis stops at total dollars.
- Psychiatry infrastructure is the strongest capital magnet even though it is not the most frequent category. Psychiatry Care Platforms accounted for 18.2% of year-to-date 2026 deals but 36.4% of dollars, which suggests investors are paying for provider capacity, medication-management workflows, and monetizable care infrastructure.
- Clinical Mental Health Apps show the opposite pattern. They account for 27.3% of year-to-date 2026 deals but only 6.5% of capital, which means AI and app-layer companies are fundable but usually not yet getting winner-level checks.
- The data rewards companies with direct reimbursement pathways. Grow Therapy, Talkiatry, Tava Health, Salma Health, and Blossom Health all tie their value propositions to payers, providers, medication management, clinics, or regulated clinical workflows rather than purely consumer self-pay demand.
- The market has shifted away from pandemic-era direct-to-consumer therapy apps toward infrastructure-plus-care models. The largest rounds increasingly go to companies embedding into insurers, employers, health systems, clinics, or provider workflows.
- March was the validation month in 2026. Six of the 11 qualifying deals and $278.0M of capital occurred in March, which means the quarter’s momentum was clustered rather than evenly distributed.
- First financings are substantial but not dominant. They represented 36.4% of year-to-date 2026 deals and 26.8% of capital, so investors are still willing to create new mental health companies, but most capital is reinforcing follow-on winners.
- Psychiatric Medication Services are unusually strong at the formation stage. Amani and Gilgamesh were both first financings, showing that new psychiatric drug-company formation remains viable when the clinical rationale is credible.
- Addiction Treatment Services are surprisingly weak in the year-to-date 2026 dataset. The likely issue is not lack of need, but difficulty producing venture-scale, repeatable, publicly disclosed financing events in a category with complex reimbursement and outcomes measurement.
- The geography split is nearly monopolized by North America. With 90.9% of year-to-date 2026 deals and 99.1% of dollars, the public venture-scale mental health funding market remains heavily U.S.-centered.
- The average year-to-date 2026 round size of $57.4M is misleading because the median is $25.0M. A realistic typical round is closer to the $20M to $40M range than to the headline average inflated by Talkiatry, Grow Therapy, and Salma Health.
- Series D+ deals made up only 18.2% of year-to-date 2026 deal count but 57.0% of capital. Late-stage private mental health companies can still raise very large checks when they show scale, payer access, and operational leverage.
- Series A is the modal stage by deal count, with 54.5% of year-to-date 2026 deals. That points to healthy company formation and early institutional validation, even though the largest dollars are concentrated later-stage.
- AI is present in many mental health narratives, but it is not being funded as magic. The strongest AI-related rounds attach AI to clinical documentation, provider workflows, patient monitoring, triage, medication decisions, billing, or care coordination.
- The strongest investor signal is not simply that mental health demand exists. It is that a company can convert demand into reimbursable care, which makes reimbursement architecture a better quality filter than user growth alone.
- Pure software for clinicians remains fundable but capital-light relative to care delivery. Oasys, Jimini, and Blossom raised meaningful rounds, but the market still gives larger balance sheets to companies closer to care delivery, psychiatry, clinics, and reimbursement.
- Mental Health Clinics are gaining credibility because they offer a way to fund higher-acuity care without relying only on virtual access models. Radial, Amae, Everbright, FamilyWell, and Salma suggest investors are increasingly interested in clinic-linked or advanced-treatment infrastructure.
- Interventional psychiatry and advanced brain-health models are re-entering the funding conversation. This matters because it expands the market beyond therapy sessions and medication management into procedural, diagnostic, and clinic-based care models.
- The funding pattern creates a useful screening rule. If a mental health startup cannot explain how it touches reimbursement, clinical capacity, outcomes, medication, or provider workflows, it is unlikely to receive top-tier capital in the current market.
- The strongest investor conviction has migrated over time. The 2024 market favored care-access platforms, 2025 favored psychiatric medication services, and early 2026 favors a mix of scaled care platforms, psychiatry infrastructure, advanced clinics, and clinical workflow software.
- The absence of repeat institutional investors in early 2026 is important. It means the mental health market is not being driven by one specialist herd; different investor groups are backing different versions of the mental health thesis.
- The most investable mental health companies increasingly combine clinical specificity with business-model specificity. “Youth mental health” or “depression care” alone is not enough without a clear channel such as schools, payers, employers, clinics, medication management, or health systems.
- The market’s center of gravity has shifted from “mental health access is underserved” to “which companies can industrialize high-quality mental health care.” That shift explains why infrastructure, psychiatry, clinics, reimbursement, and therapeutics now matter more than broad category exposure.
This chart, featured in our mental health market deck, shows how therapy matchmaking platform technology has evolved over time
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this mental health funding tracker by reviewing every publicly disclosed equity round raised by pure-play mental health companies between January 2024 and May 2026. A company counts as pure-play when more than 80% of its activity is dedicated to clinical mental health or substance-use diagnosis, treatment, care delivery, clinical management, psychiatric medication, or closely related clinical infrastructure.
We applied four filters to build the dataset. First, we only included equity rounds, so grants, debt-only financings, structured financings, acquisitions, SPAC transactions, and business combinations are excluded. Second, we only counted disclosed rounds of $300K or more. Third, we only kept pure-play mental health companies, which means we excluded general wellness, stress, lifestyle, broad primary care, non-clinical self-help, and adjacent healthcare companies that were not primarily mental health businesses. Fourth, every entry had to be confirmed by a direct company announcement, press release, tier-1 media report, specialized industry source, or relevant regional publication.
Undisclosed-amount rounds are excluded because including them would distort dollar-based metrics such as total capital, average round size, median round size, category share, and concentration ratios. Mixed equity-and-debt financings were treated carefully: when a company announced an equity financing but did not disclose the equity-only split, the round was retained with an explicit caveat rather than treated as a pure debt transaction.
The final dataset is a public-market view, not a private database export. It is designed to compare disclosed funding patterns across Therapy Care Providers, Psychiatry Care Platforms, Addiction Treatment Services, Mental Health Clinics, Clinical Mental Health Apps, and Psychiatric Medication Services. Privately raised rounds that were never publicly announced are necessarily missing, which is a known limitation of any public-only mental health funding tracker.
Related blog posts
- What is new in the mental health market lately?
- The most important recent news in the mental health market
- How big is the mental health market really?
- The most recent funding news in the mental health market
- The evolution of funding activity in the mental health market
- The startups that have raised the most funding in the mental health market
- The most highly valued startups in the mental health market
